Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
In this article, we will discuss the 15 Best Micro-Cap Stocks to Buy Now. You can skip our discussion of the merits of investing in micro-cap stocks and go directly to 5 Best Micro-Cap Stocks to Buy Now. A micro-cap stock has a market capitalization between $50 million to $1 billion. Micro-cap stocks have higher […]
One thing we could say about the analysts on Fluidigm Corporation ( NASDAQ:FLDM ) - they aren't optimistic, having just...
Shares of Fluidigm (NASDAQ: FLDM) were sinking 18.1% lower as of 11:28 a.m. EST on Thurday. Fluidigm reported that its revenue in the fourth quarter jumped 38% year over year to $44.6 million. Investors were likely especially concerned about Fluidigm's full-year 2021 guidance.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG) 9 Meters Biopharma Inc (NASDAQ: NMTR) Abbott Laboratories (NYSE: ABT) Acasti Pharma Inc (NASDAQ: ACST) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS) Agios Pharmaceuticals Inc (NASDAQ: AGIO) Alimera Sciences Inc (NASDAQ: ALIM) Alkermes Plc (NASDAQ: ALKS) Allakos Inc (NASDAQ: ALLK) Anchiano Therapeutics L...
Fluidigm (FLDM) delivered earnings and revenue surprises of -225.00% and -11.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Fluidigm (NASDAQ:FLDM) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 333.33% year over year to ($0.13), which missed the estimate of ($0.07). Revenue of $44,608,000 up by 37.51% year over year, which missed the estimate of $50,720,000. Guidance Fluidigm Sees Q1 Sales $30M-$33M vs. $47.62M Est., FY21 Sales $144M-$155M Vs. $198.25M Est. How To Listen To The Conference Call Date: Feb 10, 2021 Time: 05:00 PM View more earnings...
Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to $138.1 millionCollaboration with PLT Tech to Market CyTOF Technology to Clinical Labs in China SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,...